logo

For the Inventor, By the Inventor

Oxford, United Kingdom

Matthew Colin Thor Fyfe

This inventor holds 17 USPTO granted patents and 24 published patent applications and 10 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Prosidion Limited, Warner-Lambert Company, Sitryx Therapeutics Limited. Active years: 2006-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthew Colin Thor Fyfe. Retrieved from https://idiyas.com/inventor/matthew-colin-thor-fyfe-47vcc1i3

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17 

% Patents Active = 17.6

 

Average Co-Inventor Count = 5.1

ph-index = 3

Forward Citations = 27(Granted Patents)


Location History:

  • Witney, GB (2006)
  • Oxford, GB (2007 - 2012)

Company Filing History:

goldMedal7 out of 16 
 
Prosidion Limited
 patents
silverMedal6 out of 2,538 
 
Warner-Lambert Company
 patents
bronzeMedal4 out of 6 
 
Sitryx Therapeutics Limited
 patents

Years Active: 2006-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Anti-Inflammatory Compounds
GPCR Agonists
Glucokinase Activators
Heterocyclic Derivatives
Pyridine Derivatives
Androgen Receptor Antagonists
Carboxy Derivatives
Thiourea Derivatives
Phenylacetamides
Methacrylic Esters
Urea Derivatives
Sulfonamide Derivatives
17 patents (USPTO):Explore Patents
1. 12678419 - Compounds (2026-07-14),
2. 12617762 - Carboxy derivatives with antiinflamatory properties (2026-05-05),
3. 12459908 - Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties (2025-11-04),
4. 12390437 - Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response (2025-08-19),
5. 8207147 - Heterocyclic derivatives as GPCR receptor agonists (2012-06-26),
6. 8193359 - G-protein coupled receptor agonists (2012-06-05),
7. 8173807 - Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists (2012-05-08),
8. 7745491 - Substituted phenylacetamides and their use as glucokinase activators (2010-06-29),
9. 7582632 - Tri(cyclo) substituted amide compounds (2009-09-01),
10. 7262196 - Tri(cyclo) substituted amide glucokinase activator compounds (2007-08-28),
11. 7214681 - Tri(cyclo) substituted amide compounds (2007-05-08),
12. 7115745 - Benzyl urea and thiourea derivatives (2006-10-03),
13. 7098340 - Benzyl sulfonamide derivatives (2006-08-29),
14. 7074933 - Urea and thiourea derivatives (2006-07-11),
15. 7064207 - Androgen receptor antagonists (2006-06-20),

Title: Biography of Matthew Colin Thor Fyfe

Introduction: Matthew Colin Thor Fyfe is an accomplished inventor based in Oxford, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target G-protein coupled receptors.

Latest Patents: Fyfe holds 13 patents, with his latest innovations focusing on heterocyclic derivatives as GPCR receptor agonists. These compounds are designed to regulate satiety and are useful in the treatment of obesity and diabetes. His work includes compounds of Formula (I), R-A-V—B—R, and their pharmaceutically acceptable salts, which act as agonists of GPR116.

Career Highlights: Throughout his career, Fyfe has worked with notable companies such as Prosidion Limited and Warner-Lambert Company. His expertise in pharmacology and receptor biology has positioned him as a key figure in the development of new therapeutic agents.

Collaborations: Fyfe has collaborated with esteemed colleagues, including Martin James Procter and Vilasben Kanji Shah. These partnerships have enhanced his research and contributed to the advancement of innovative solutions in the pharmaceutical industry.

Conclusion: Matthew Colin Thor Fyfe's work exemplifies the impact of innovation in medicine. His patents and collaborations reflect a commitment to addressing critical health issues, particularly obesity and diabetes, through scientific research and development.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…